Valemetostat tosylate
Phase 2Small molecule
Daiichi SankyoValemetostat tosylate is one of 137 small molecule programs targeting Relapsed/Refractory Peripheral T-cell Lymphoma. It is currently in Phase 2.
5
Indications
7
Total Trials
6
Active Trials
136
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Navelbine
PPierre Fabre Medicament
Phase 3
Pyrotinib
HHengrui Therapeutics, Inc.
Phase 3
Carboplatin/paclitaxel
AstraZenecaPhase 3
Valemetostat tosylate
Daiichi SankyoPhase 2
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma1 trial
Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
Active, not recruiting·TThe Lymphoma Academic Research Organisation·Phase 2·NCT04842877·141 enrolled
Efficacy and Safety1 trial
Adult T-Cell Leukemia/lymphoma1 trial
Solid Tumor1 trial
2 more indications
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Valemetostat tosylate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company